FDA approved drug for treatment of breast cancer which is ER positive: (AIIMS Nov 2009)
(Ref: BG Katzung, Basic & Clinical Pharmacology’ 11th Edition’ 2010; pp-716)
a. Tamoxifen is a non steroidal compound and is SERM. It is an agonist at uterus and bones and is an antagonist of estrogens at breast. It is well absorbed orally and has a half life of around 24 hours. Elimination is by bile.
b. It up regulates TGFbeta and has been approved by FDA for treatment of advanced estrogen receptor positive (ER +ve) breast cancer as an adjutant or to reduce risk of breast cancer in women with high risk. Most common side effects are flushing and hyperlipdemia.
c. Most serious side effect is endometrial hyperplasia leading to endometrial cancer.